We're the first mate. The second is also being run by City of Hope, but with different exclusion criterion and aims. They use CAR-T armed with Interleukin 13 R alpha2, whilst we've got the CLTX target receptor which is what makes CHM's IP so exciting.., In that clinical trial you've outlined, they are co-using the therapy with Opdivo and Yervoy biologics.
CAR-T, the therapy time as a whole is short for Chimeric Antigen Receptor-Therapy used to describe the process of arming T-cells with specific receptor types. Chlorotoxin (CLTX) relates to our receptor ligand target.
We're the first mate. The second is also being run by City of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $12.99M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $949 | 312.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 70 | 67782438 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 91927011 | 27 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |